Market Place
Sourcing Support
Devonian Reports Its Annual 2024 Financial Results
29 Nov 2024 //
BUSINESSWIRE
Devonian Announces the Grant of Stock Options
08 Oct 2024 //
BUSINESSWIRE
Devonian Health Group To Participate In Chicago Virtual Roadshow
15 Jul 2024 //
BUSINESSWIRE
Devonian Health To Join Renmark`s LA Virtual Non-Deal Roadshow
08 Jul 2024 //
BUSINESSWIRE
Devonian Health Group Reports Q3 2024 Results, Engages Investor Relations Firm
25 Jun 2024 //
BUSINESSWIRE
Devonian Health Group to Join Renmark’s Boston Virtual Roadshow
25 Jun 2024 //
BUSINESSWIRE
Devonian Appoints André Boulet Chairman & COO
03 Jun 2024 //
BUSINESSWIRE
Devonian Reports Second Quarter 2024 Financial Results and Business Update
28 Mar 2024 //
BUSINESSWIRE
Devonian Announces Closing of a Private Placement of Units
14 Mar 2024 //
BUSINESSWIRE
Devonian Names Kathryn J. Gregory to Board of Directors and Grants Stock Options
29 Feb 2024 //
BUSINESSWIRE
Altius, Launches Authorized Generic of Dexlansoprazole (Dexilant®) in Canada
27 Feb 2024 //
BUSINESSWIRE
Devonian Announces a $2.16 Million Secured Term Loan
26 Feb 2024 //
BUSINESSWIRE
Devonian Announces Results of Annual General and Special Shareholders` Meeting
21 Feb 2024 //
BUSINESSWIRE
Devonian Bolsters Intellectual Property With Issuance of U.S. Patent
20 Feb 2024 //
BUSINESSWIRE
Devonian Bolsters Leadership Team and Aligns Strategy
04 Dec 2023 //
BUSINESSWIRE
Devonian Group Receives a Notice of Allowance for Issuance of a U.S. Patent
20 Jun 2023 //
BUSINESSWIRE
Devonian Announces Closing of a Private Placement of $1.2 Million
06 Jun 2023 //
BUSINESSWIRE
Devonian Announces Private Placement of up to $5 Million
19 May 2023 //
BUSINESSWIRE
Devonian Health Group Announces Presentation of Thykamine™
16 May 2023 //
BUSINESSWIRE
Devonian Announces Appointment of New Board Members and Grant of Stock Options
12 May 2023 //
BUSINESSWIRE
Devonian Announces Approval of Amendments to its Stock Option Plan
30 Mar 2023 //
BUSINESSWIRE
Devonian Health Group Announces voting results of the Annual General
24 Mar 2023 //
BUSINESSWIRE
Devonian Announces Hybrid Shareholders’ Annual General and Special Meeting
22 Feb 2023 //
BUSINESSWIRE
Devonian Health Announces its Participation at BIO CEO & Investor Conference
26 Jan 2023 //
BUSINESSWIRE
Devonian Health Group Announces Executive Change and Grant of Stock Options
06 Jan 2023 //
BUSINESSWIRE
Devonian to Present Thykamine PII Results at Dermatology Drug Development Summit
12 Oct 2022 //
BUSINESSWIRE
Devonian Announces Publication of Thykamine Positive PII Trial Results
06 Oct 2022 //
BUSINESSWIRE
Devonian Announces the Issuance of Units in Settlement of Interests
07 Sep 2022 //
BUSINESSWIRE
Devonian Announces Executive Changes, Grant of Stock Options
29 Aug 2022 //
BUSINESSWIRE
Devonian Health on Thykamine Positive PII Trial Results in Atopic Dermatitis
26 May 2022 //
BUSINESSWIRE
Alpine Immune Sciences Reports Q4 and FY 2021 Financial Results
17 Mar 2022 //
BUSINESSWIRE
Devonian Health Group Announces Trading on the OTCQB Market Under Symbol DVHGF
10 Mar 2022 //
BUSINESSWIRE
Devonian to Issue Units in Settlement of Interests Owed to Debenture Holders
07 Mar 2022 //
BUSINESSWIRE
Devonian Health Announces Voting Results of Annual General and Special Meeting
01 Mar 2022 //
BUSINESSWIRE
Devonian Issues Units in Settlement of Interests Owed to Debenture Holder
31 Jan 2022 //
BUSINESSWIRE
Devonian Announces Adoption of Shareholder Rights to a Private Placement
27 Jan 2022 //
BUSINESSWIRE
Devonian Announces the Issuance of Subordinate Voting Shares
24 Nov 2021 //
BUSINESSWIRE
Devonian Health Announces Appointment of Martin Moreau as Vice-President Finance
30 Sep 2021 //
BUSINESSWIRE
Devonian Health Group Announces Closing of a Private Placement
13 Sep 2021 //
BUSINESSWIRE
Devonian Announces the Issuance of Units in Settlement of Interests Owed
08 Sep 2021 //
BUSINESSWIRE
DEVONIAN HEALTH GROUP ANNOUNCES DISTRIBUTION, SALE AND MARKETING AGREEMENT
31 Aug 2021 //
BUSINESSWIRE
Devonian Group Announces Participation at Virtual BioPlus-Interphex Korea 2021
26 Aug 2021 //
BUSINESSWIRE
Devonian Announces the Issuance of Units in Settlement of Interests Owed
29 Jul 2021 //
BUSINESSWIRE
DEVONIAN HEALTH GROUP ANNOUNCES PARTICIPATION IN RENMARK VNDR SERIES
27 Jul 2021 //
PR NEWSWIRE
Devonian Heath to Participate in Renmark’s Virtual Non-deal Roadshow Series
27 Jul 2021 //
PR NEWSWIRE
Devonian Announces the Issuance of Units in Settlement of Interests Owed
27 Jul 2021 //
PR NEWSWIRE
Devonian Health Group Announces Notice of Allowance for a US Patent
30 Mar 2021 //
BUSINESSWIRE
Devonian Health Group Provides More Details on Previously Announced Positive
25 Mar 2021 //
BUSINESSWIRE
Devonian Health Group Announces Positive Topline Results from Phase 2
18 Feb 2021 //
BUSINESSWIRE
Devonian Health Group Announces Results from Ph 2 trial of Thykamine™
18 Feb 2021 //
BUSINESSWIRE
Devonian Announces the Issuance of Units in Settlement of Interests Owed
09 Oct 2020 //
YAHOO
Devonian Announces the Issuance of Units in Settlement of Interests Owed
09 Oct 2020 //
BUSINESSWIRE
Devonian Health Group Announces Notice of Allowance for a US Patent Thykamine™
15 Jun 2020 //
BUSINESSWIRE
